Lung Cancer News

Dabrafenib/Trametinib Active in Treatment-naive Patients With NSCLC

Dabrafenib/Trametinib Active in Treatment-naive Patients With NSCLC

Results from 2 other cohorts of this phase 2 study demonstrated that genotype-directed therapy with dabrafenib plus trametinib was effective in previously treated patients with BRAFV600E-mutant NSCLC.

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

Phase 3 Motesanib Trial for East Asian Patients With NSCLC Misses Primary Endpoint

Phase 3 Motesanib Trial for East Asian Patients With NSCLC Misses Primary Endpoint

For this randomized phase 3 study, patients were assigned to motesanib plus paclitaxel and carboplatin (197 patients) or to placebo plus paclitaxel and carboplatin (204 patients).

Nintedanib Prolongs Progression-free Survival in Mesothelioma

Nintedanib Prolongs Progression-free Survival in Mesothelioma

Researchers randomly assigned 87 patients with unresectable, non-sarcomatoid MPM to receive 6 cycles of standard pemetrexed and cisplatin with nintedanib 200 mg twice daily or placebo, followed by nintedanib or placebo monotherapy.

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive cellular immunotherapy has not been widely used for cancer treatment.

First Line Osimertinib May Be Effective in EGFR Mutation Positive NSCLC

First Line Osimertinib May Be Effective in EGFR Mutation Positive NSCLC

Previously collected data from the AURA study demonstrated that osimertinib may be effective as first-line therapy for this patient population.

Canakinumab May Decrease Risk of Incident Lung Cancer

Canakinumab May Decrease Risk of Incident Lung Cancer

In a secondary analysis of the CANTOS trial, researchers analyzed the effect canakinumab's inhibition of interleukin-1β may have on the risk of cancer.

Everolimus Maintains Quality of Life in Neuroendocrine Tumors

Everolimus Maintains Quality of Life in Neuroendocrine Tumors

A previous analysis demonstrated that everolimus prolonged progression-free survival — the primary endpoint of the study — compared with placebo.

High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention

High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention

Increased vitamin B intake is hypothesized to interfere with the one-carbon metabolism pathway, a process that is thought to be important for gene expression regulation and DNA integrity maintenance, thereby increasing carcinogenic risk.

Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer

Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer

Atezolizumab monotherapy has a good overall response rate (ORR) and favorable safety profile in patients with advanced PD-L1 expressing non-small cell lung cancer (NSCLC).

NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis

NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis

Compared with ALK¬-positive patients, participants with ROS1 rearrangements were less likely to present with extrathoracic and brain metastases.

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).

Higher Opioid Prescription Rates Among Survivors of Cancer

Higher Opioid Prescription Rates Among Survivors of Cancer

Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.

Alectinib Granted FDA Priority Review for ALK-positive NSCLC

Alectinib Granted FDA Priority Review for ALK-positive NSCLC

The FDA granted priority review to alectinib for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC.

FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters